Skip to content
Screener

Omeros OMER Return on equity

Discontinued — last reported Q4 '22

Return on equity at other companies

Immunome logo
ImmunomeIMNM
-50.1%-10.8pp
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-44%+26.2pp
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-53.6%-22.6pp
Annexon logo
AnnexonANNX
-87.6%+42.3pp
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-37.8%—
Vor Biopharma logo
Vor BiopharmaVOR
-125.4%+671pp

Other financials

Income statement

See full
Revenue$9.9M—
Gross profit$29.7M—
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$958.97M+245%
P/S10.7×—

Profitability

See full
Gross margin98.9%—
Operating margin-181.8%—
Net margin-136.6%—
FCF margin-121.6%—

Returns & leverage

See full
Debt / equity0.3×-1.1×
Current ratio3×+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

net income/total stockholders equity=86.6%

Based on trailing twelve months.

The source filing: Omeros’s 10-Q, filed August 9, 2023. Open the filing →

Filed
Aug 9, 2023
Fiscal quarter
Q2 FY2023
Calendar quarter
Q2 2023
Accession
0001558370-23-014095

FAQ

What is Omeros's return on equity?
Omeros (OMER) reported return on equity of 86.6% in Q4 2022.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Omeros's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude